We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

72 hedge funds and large institutions have $273M invested in Albireo Pharma Inc in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

40% more capital invested

Capital invested by funds: $195M → $273M (+$78.2M)

30% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 20

6% more funds holding

Funds holding: 68 → 72 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

53% less call options, than puts

Call options by funds: $193K | Put options by funds: $412K

Holders
72
Holders Change
+4
Holders Change %
+5.88%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
26
Reduced
20
Closed
1
Calls
$193K
Puts
$412K
Net Calls
-$219K
Net Calls Change
-$170K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.57M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$3.59M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$1.3M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.17M
5
MWNA
Marshall Wace North America
New York
+$682K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.64M
2
Renaissance Technologies
Renaissance Technologies
New York
-$358K
3
Morgan Stanley
Morgan Stanley
New York
-$332K
4
BlackRock
BlackRock
New York
-$304K
5
Victory Capital Management
Victory Capital Management
Texas
-$236K
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
51
MetLife Investment Management
New Jersey
$152K – – –
Bank of Montreal
52
Bank of Montreal
Ontario, Canada
$148K +$3.53K +131 +3%
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
$107K – – –
Bank of America
54
Bank of America
North Carolina
$91K -$97.3K -3,616 -56%
SO
55
STRS Ohio
Ohio
$86K – – –
Barclays
56
Barclays
United Kingdom
$86K +$67.9K +2,523 +1,649%
Citigroup
57
Citigroup
New York
$74K -$3.69K -137 -6%
JP Morgan Chase
58
JP Morgan Chase
New York
$72K -$2.8K -104 -4%
Morgan Stanley
59
Morgan Stanley
New York
$70K -$332K -12,336 -85%
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$61.1K +$45.7K +1,697 +849%
Marshall Wace
61
Marshall Wace
United Kingdom
$61K – – –
Legal & General Group
62
Legal & General Group
United Kingdom
$53K +$7.38K +274 +20%
PCM
63
Prelude Capital Management
New York
$24K -$2.75K -102 -12%
AIP
64
Ameritas Investment Partners
Nebraska
$22K – – –
Simplex Trading
65
Simplex Trading
Illinois
$14K -$4.15K -154 -26%
CCM
66
Cribstone Capital Management
Maine
$10K – – –
TRCT
67
Tower Research Capital (TRC)
New York
$7K -$11.9K -442 -66%
MAM
68
Meeder Asset Management
Ohio
$7K +$942 +35 +18%
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
$3K – – –
PMFA
70
Plante Moran Financial Advisors
Michigan
$2K – – –
UBS Group
71
UBS Group
Switzerland
$1K -$89.6K -3,329 -99%
PFGIA
72
Patriot Financial Group Insurance Agency
Massachusetts
$1K +$673 +25 New
1 2
3

ALBO Hedge Fund Activity: Q1 2019 in Review

72 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2019, worth a combined $273M — up 40% from $195M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ALBO positions and 1 closed out — a net gain of 4 holders — while 26 added to existing stakes and 20 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $4.57M. The largest seller was Fidelity Investments, cutting an estimated $1.64M.

  • 72 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2019, up from 68 in Q4 2018.
  • Funds reported $273M of Albireo Pharma Inc stock for Q1 2019, up 40% quarter-over-quarter.
  • 5 funds opened new Albireo Pharma Inc positions in Q1 2019 and 1 closed out, a net change of +4 holders.
  • The largest Albireo Pharma Inc buyer in Q1 2019 was Point72 Asset Management, an estimated $4.57M added.
  • The largest Albireo Pharma Inc seller in Q1 2019 was Fidelity Investments, an estimated $1.64M sold.

Based on aggregated 13F filings for Q1 2019.